AstraZeneca announced that its cancer drug, Imfinzi, has met the second of two primary endpoints in the phase III PACIFIC trial, showing a “statistically-significant” benefit to overall survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease hadn’t improved after a course of chemotherapy and radiation therapy.
The company said the results of the interim analysis of the PACIFIC trial provide compelling evidence of the clinical benefit that Imfinzi can offer patients with NSCLC.
In May 2017, AstraZeneca announced that the PACIFIC trial met its first primary endpoint of PFS by demonstrating a median improvement of 11.2 months vs. placebo, as assessed by blinded independent central review. Imfinzi was approved in the U.S. and Canada for use in this subset of patients earlier this year
Read the press release